CL

Business profile & competitive position

Colgate-Palmolive Company is a Consumer Defensive name in the Household & Personal Products industry. Its product set spans toothpaste, toothbrushes, soaps, deodorants, skin-health products, cleaners, fabric conditioners, and specialty pet nutrition through Hill’s Pet Nutrition. With operations in over 200 countries and territories, the business sits in a segment where repeat purchases, shelf presence, and brand recognition matter more than cyclical demand.

The reported financial metrics mix steady consumer-staples characteristics with balance-sheet mechanics that need careful interpretation. Net margin is 9.7% — solidly profitable for packaged goods, though not eye-popping on its own. The ROE of 631.1% is extraordinarily high and, for a mature capital-return-heavy company, usually signals aggressive financial leverage, share buybacks, or a shrunk/negative equity base rather than a pure operating-moat metric. Paired with a beta of 0.32, the picture is one of a stable-demand, low-market-sensitivity business that uses its balance sheet actively to amplify returns to equity holders. The moat therefore looks anchored in brand equity, distribution reach, and repeat-consumption habits, while the headline ROE is mostly a financial-structure outcome.

Financial posture

CL currently carries a market capitalization of $74.3 billion and trades at a P/E of 36.6. That multiple looks like a premium relative to the broader staples complex, implying the market is paying up for earnings stability and global brand strength. The net margin of 9.7% supports a steady cash-flow profile, while the 631.1% ROE underlines how aggressively the company has deployed leverage and capital returns.

A beta of 0.32 places CL firmly in the defensive camp: its equity price historically moves much less than the overall market, which is consistent with non-discretionary toothpaste, soap, and pet-food demand. The current share price is $93.17, with a 50-day EMA of $89.17 and an RSI of 68.6. The RSI near 68.6 suggests the stock has been run up toward the upper end of recent momentum, though by itself RSI does not predict direction. In sum, the financial posture is one of a premium-valued, low-volatility consumer franchise backed by reliable margins and an unusually leveraged return-on-equity profile.

Strategic priorities & outlook

Colgate-Palmolive’s most recent 10-K frames four operational priorities: drive organic sales growth and consistent compounded EPS growth; achieve operational efficiencies while growing free cash flow and using the balance sheet efficiently; leverage global brand reach, science-based innovation, an agile supply chain, and best-in-class omni-channel demand generation; and build capabilities in data, analytics, and artificial intelligence while evolving an inclusive culture.

The segment split reported for 2025 shows where the revenue actually comes from: Oral Care at 44% of worldwide net sales, Pet Nutrition at 23%, Personal Care at 17%, and Home Care at 16%. That makes Oral Care the dominant engine, but Pet Nutrition is meaningfully larger than Personal or Home Care. Walmart and its affiliates represented approximately 11% of 2025 net sales, making the company somewhat dependent on the largest U.S. retailer even though no other customer exceeded 10%. Operationally, CL had about 33,600 employees as of December 31, 2025, across more than 100 countries, with over 84% located outside the United States — a footprint that underscores how global currency, trade, and local competitive dynamics feed directly into growth and margin.

Macro & geopolitical exposure

Because Household & Personal Products sit in the non-discretionary consumer space, demand for CL’s products tends to be resilient. Still, the classification carries real exposures. Raw-material inputs — surfactants, palm-oil derivatives, petroleum-based packaging, and fragrances — are sensitive to commodity cycles and energy prices. Freight and logistics costs also move with fuel and labor markets, so inflation or supply-chain disruption can pressure gross margins.

With over 84% of employees outside the U.S. and sales spread across more than 200 territories, foreign-exchange translation is a recurring factor. A stronger U.S. dollar reduces the dollar value of overseas earnings, while a weaker dollar has the opposite effect. Trade policy, tariffs, and local regulatory regimes also matter: ingredients used in oral care, personal care, and pet food face labeling, safety, and environmental rules that differ by country. Retailer concentration is another industry-level risk; in CL’s case, Walmart alone accounts for roughly 11% of annual net sales, giving that relationship meaningful bargaining leverage. Finally, private-label competition and the growth of e-commerce and direct-to-consumer channels are ongoing competitive pressures across the sector.

Recent developments

The latest item in the dataset is an October 18, 2026 Gurufocus.com headline about ESMO 2026 presentations deepening the evidence base for Natera’s oncology portfolio. That story is not about Colgate-Palmolive’s operations, but it appeared in the same earnings-intelligence feed, illustrating how algorithmic news aggregation can bundle unrelated tickers.

The more directly relevant news came from Business Wire on October 16, 2026: Colgate-Palmolive scheduled its third-quarter 2026 earnings conference call for October 30, 2026 at 8:30 a.m. ET. Seeking Alpha, also on October 16, 2026, included CL in its “Dividend Champion, Contender, And Challenger Highlights” roundup. A day earlier, on October 15, 2026, 247WallSt.com featured Colgate-Palmolive among “5 Dividend Stocks That Turn Everyday Shopping Habits Into Retirement Income.” That dividend angle aligns with how income-oriented investors often treat low-beta consumer staples. For the upcoming report, the consensus EPS estimate is $0.927.

Earnings behavior & post-earnings drift

CL has delivered an 8-for-8 beat rate over the last eight reported quarters, with an average earnings surprise of 3.3%. More interesting is how the stock behaves after the prints. Across those same eight quarters, the average 5-day price move following earnings was +2.32%, classified as an “up” drift. That pattern is not visible in the immediate next-day reaction alone.

Looking at the last four reported quarters, the detail is clearer:

• On July 31, 2026, CL reported EPS of $0.99 against an estimate of $0.947, a 4.5% beat. The stock fell 1.56% the next day but rose 2.16% over the following five sessions.
• On May 1, 2026, EPS came in at $0.97 versus $0.943, a 2.9% beat. The next-day move was -2.17%, yet the five-day drift was +0.33%.
• On January 30, 2026, EPS was $0.95 versus $0.912, a 4.2% beat. The stock rallied 1.77% the next day and extended that to a 4.56% gain over five days.
• On October 31, 2025, EPS was $0.91 versus $0.889, a 2.4% beat. The next day dropped 2.69%, but the five-day drift was +2.22%.

Three of the four most recent prints saw a negative next-day reaction despite outperforming consensus, while the post-earnings drift over five days was positive in all four instances. That divergence suggests that short-term price action can underreact, over-dissect guidance, or absorb macro-driven risk-off flows, while the market’s real expectation of steady execution tends to reassert itself within a week. With the next report scheduled for October 30, 2026 before the open, the consensus EPS estimate is $0.927.

For a deeper dive into how institutional analysts, quantitative models, and options markets are positioned around Colgate-Palmolive ahead of the October 30 report, review the full institutional verdict on the ticker page.